Smoking in Germany
In Germany, smoking is allowed but regulated under national tobacco control laws. Cigarettes can be legally sold with a license, purchased online, and bought from vending machines. Importation for trade is also permitted with a lincense. Health warnings on packaging are compulsory, and the minimum age for purchasing tobacco products is 18 years. Nonetheless, a fully comprehensive smoke-free ban in all public places is not in place. Cigarettes are taxed at an overall rate of 64.44% and an excise rate of 29%. Despite this regulatory framework, Germany recorded approximately 13.9 million current adult smokers in 2024, corresponding to an adult smoking prevalence of 19.3%, while in 2022, this was 18.8%. Smoking prevalence was higher among men (22.1%) than among women (16.5%) in 2024. The adult daily smoking prevalence was 21.6% in 2023. In terms of health impact, smoking caused 98,991 deaths in 2021, including 70,315 among men and 28,676 among women. Overall, smoking resulted in 9.82% of all deaths in Germany in 2021, comprising 13.84% of all male deaths and 5.73% of all female deaths.
Read articles from Germany
November 18, 2026 by tobaccoreporter.com
Crime Stoppers Targeting EU’s Illicit Nicotine Market
Crime Stoppers International has launched a European campaign encouraging the public to report illegal sellers of vapes and nicotine pouches anonymously.
Citing research suggesting that nearly half of vapes sold across Europe are non-compliant or illegal, the campaign highlights growing concerns about organised crime, counterfeit products and inadequate consumer safeguards.
Recent enforcement operations in Germany and Lithuania have uncovered large-scale illegal vape imports and counterfeit nicotine pouch production. The developments underline the importance of effective enforcement alongside clear regulation that protects consumers and maintains access to legitimate, lower-risk nicotine alternatives.
November 17, 2026 by clearingtheair.eu
European Parliament nicotine event access row raises Article 5.3 questions
A European Parliament event examining the science of emerging nicotine products has faced criticism after several tobacco harm reduction advocates reported being denied access.
Organisers cited WHO tobacco treaty provisions restricting industry influence, while critics questioned the exclusion of independent advocates and the involvement of a pharmaceutical company producing nicotine replacement therapies.
The controversy raises broader questions about transparency, conflicts of interest and scientific debate in EU tobacco policy. Evidence-based regulation requires open scrutiny of competing perspectives, particularly on the relative risks of nicotine products and their potential role in reducing smoking-related harm.
October 23, 2026 by clearingtheair.eu
German tax blunder leaves vape duty missing in action
A drafting error in Germany's tobacco tax legislation has created uncertainty over e-liquid duties for the remainder of 2026. The revised law took effect earlier than intended, while new vaping tax rates are not scheduled to begin until January 2027.
Industry representatives argue that the mistake has left a temporary gap in taxation, although the Finance Ministry maintains that existing rates remain valid.
The dispute highlights the importance of regulatory clarity for businesses and consumers. Beyond administrative errors, nicotine taxation should provide predictable rules while recognising the role of affordable smoke-free alternatives in reducing smoking-related harm.
October 06, 2026 by gfn.tv
Is Regulation Ignoring the Evidence? The Challenge of Better Regulation | #GFN26 Science Lab
Better regulation begins with a simple discipline: look at the evidence before deciding what the policy should say. In tobacco and nicotine control, that means distinguishing between products, measuring actual exposure, and asking whether rules help smokers move away from combustion. Regulation that ignores evidence may still look decisive, but it can harden the wrong incentives and leave the greatest harms untouched. The challenge is not more regulation for its own sake — it is regulation that is proportionate, responsive and honest about risk.
September 30, 2026 by snusforumet.se
Why are Europe’s cancer organisations targeting nicotine?
Cancer prevention depends on identifying the exposures that drive disease burden. In tobacco use, the principal risk arises from combustion and the resulting toxicants, rather than nicotine itself. Conflating nicotine with smoking can weaken public understanding of relative risk and obscure the potential role of smoke-free alternatives for adults who continue to smoke. Public health communication should distinguish clearly between dependence, exposure and disease causation.
September 23, 2026 by 2firsts.com
Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
A nicotine substitute entering the market before key human evidence is available should make regulators ask better questions, not reach for easy assumptions. New molecules such as 6-methyl nicotine may sit outside familiar tobacco and nicotine frameworks, but that does not make them automatically safer, riskier or irrelevant. The priority should be transparent testing, pharmacology, exposure data and real-world monitoring before public health claims are made. Innovation can support harm reduction only when the evidence keeps pace with the product.
September 23, 2026 by 2firsts.com
Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
A nicotine substitute entering the market before key human evidence is available should make regulators ask better questions, not reach for easy assumptions. New molecules such as 6-methyl nicotine may sit outside familiar tobacco and nicotine frameworks, but that does not make them automatically safer, riskier or irrelevant. The priority should be transparent testing, pharmacology, exposure data and real-world monitoring before public health claims are made. Innovation can support harm reduction only when the evidence keeps pace with the product.
September 17, 2026 by substack.com
Europe Is Protecting Cigarettes from Their Competitors
Europe’s nicotine policy risks protecting cigarettes from competition by making safer alternatives harder to access, afford or communicate clearly. That is a dangerous inversion of public health priorities: the most harmful product remains familiar while lower-risk options face suspicion and restriction. Adult smokers need a market where moving away from combustion is easier than staying with it. Regulation should challenge cigarettes, not shield them from the products that could make them less dominant.
July 27, 2026 by yahoo.com
Op-Ed: No air conditioning, but Brussels wants to ban Zyn
Heat is no longer an abstract climate issue when people are trying to sleep, work or stay safe in homes built for a cooler past. The air-conditioning debate shows how quickly adaptation becomes political: some see cooling as wasteful, others as basic protection against extreme heat. A serious response should not shame people for needing relief, but make cooling cleaner, more efficient and more accessible. Climate policy has to help people live with the risks already here, not only argue about the emissions still to come.
May 08, 2026 by internationalcbc.com
How Many Jurisdictions Want Cannabis Pilot Trials In Germany?
Europe permits limited recreational cannabis commerce for research purposes through pilot trials, allowing local consumers, producers, and retailers to participate. Switzerland and the Netherlands have successful pilot projects, while Germany recently passed the CanG measure legalizing personal cannabis use and cultivation. Despite interest, Germany has not yet approved any pilot trial applications. Research aims to evaluate economic, health-related, and social impacts, potentially influencing broader legalization in Germany and the EU. Success in Switzerland and the Netherlands indicates Germany could also effectively implement pilot trials.
- Page 1 of 4